BACKGROUND: Peroxisome proliferator-activated receptor gamma (PPARγ) agonists have beneficial effects on renal structure and function in models of diabetes and chronic kidney diseases. However, the increased incidence of weight gain and edema potentially limits their usefulness. We studied an acute minimal-change disease-like nephrotic syndrome model to assess effects of PPARγ agonist on acute podocyte injury and effects on fluid homeostasis. METHODS: Acute podocyte injury and nephrotic syndrome were induced by puromycin aminonucleoside (PAN) injection in rats. RESULTS: PPARγ agonist, given at the time or after, but not before PAN, reduced proteinuria, restored synaptopodin, decreased desmin and trended to improve foot process effacement. There was no significant difference in glomerular filtration, effective circulating volume, blood pressure or fractional sodium excretion. PAN-injured podocytes had decreased PPARγ, less nephrin and α-actinin-4, more apoptosis and reduced phosphorylated Akt. In PAN-injured cultured podocytes, PPARγ agonist also reversed abnormalities only when given simultaneously or after injury. CONCLUSIONS: These results show that PPARγ agonist has protective effects on podocytes in acute nephrotic syndrome without deleterious effects on fluid homeostasis. PPARγ agonist-induced decrease in proteinuria in acute nephrotic syndrome is dependent at least partially on regulation of peroxisome proliferator-response element-sensitive gene expression such as α-actinin-4 and nephrin and the restoration of podocyte structure.
BACKGROUND:Peroxisome proliferator-activated receptor gamma (PPARγ) agonists have beneficial effects on renal structure and function in models of diabetes and chronic kidney diseases. However, the increased incidence of weight gain and edema potentially limits their usefulness. We studied an acute minimal-change disease-like nephrotic syndrome model to assess effects of PPARγ agonist on acute podocyte injury and effects on fluid homeostasis. METHODS: Acute podocyte injury and nephrotic syndrome were induced by puromycin aminonucleoside (PAN) injection in rats. RESULTS: PPARγ agonist, given at the time or after, but not before PAN, reduced proteinuria, restored synaptopodin, decreased desmin and trended to improve foot process effacement. There was no significant difference in glomerular filtration, effective circulating volume, blood pressure or fractional sodium excretion. PAN-injured podocytes had decreased PPARγ, less nephrin and α-actinin-4, more apoptosis and reduced phosphorylated Akt. In PAN-injured cultured podocytes, PPARγ agonist also reversed abnormalities only when given simultaneously or after injury. CONCLUSIONS: These results show that PPARγ agonist has protective effects on podocytes in acute nephrotic syndrome without deleterious effects on fluid homeostasis. PPARγ agonist-induced decrease in proteinuria in acute nephrotic syndrome is dependent at least partially on regulation of peroxisome proliferator-response element-sensitive gene expression such as α-actinin-4 and nephrin and the restoration of podocyte structure.
Authors: George L Bakris; Luis M Ruilope; Stephen O McMorn; Wayde M Weston; Mark A Heise; Martin I Freed; Lisa E Porter Journal: J Hypertens Date: 2006-10 Impact factor: 4.844
Authors: Konstantinos B Sotiropoulos; Allen Clermont; Yutaka Yasuda; Christian Rask-Madsen; Motonobu Mastumoto; Junichi Takahashi; Kim Della Vecchia; Tatsuya Kondo; Lloyd P Aiello; George L King Journal: FASEB J Date: 2006-05-03 Impact factor: 5.191
Authors: Jian Song; Mark A Knepper; Xinqun Hu; Joseph G Verbalis; Carolyn A Ecelbarger Journal: J Pharmacol Exp Ther Date: 2003-10-30 Impact factor: 4.030
Authors: Frances Kindt; Elke Hammer; Stefan Kemnitz; Antje Blumenthal; Paul Klemm; Rabea Schlüter; Susan E Quaggin; Jens van den Brandt; Georg Fuellen; Uwe Völker; Karlhans Endlich; Nicole Endlich Journal: Br J Pharmacol Date: 2016-12-20 Impact factor: 8.739
Authors: Yiqin Zuo; Bongkwon Chun; Sebastian A Potthoff; Naj Kazi; Tyler J Brolin; Diclehan Orhan; Hai-Chun Yang; Li-Jun Ma; Valentina Kon; Timo Myöhänen; Nour-Eddine Rhaleb; Oscar A Carretero; Agnes B Fogo Journal: Kidney Int Date: 2013-06-05 Impact factor: 10.612